The Asia Pacific cancer therapies market size was valued at USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of 10.2% during 2023 – 2031. The growth of the market is attributed to the rising cases of people having cancer.
Cancer is a disease characterized by uncontrolled cell proliferation. It is one of the world's worst diseases and the second leading cause of death. Cancer is a type of abnormal cell development that can spread to other parts of the body. Humans have been impacted by approximately 100 different forms of cancer.
According to the American Cancer Society, 4.2 new instances of aggressive cancer were identified in China in 2015. There has been a considerable increase in the number of individuals suffering from various forms of cancer over the previous decade. One of the most significant risk factors for cancer is smoking. The most frequent cancers in China include lung, stomach, colorectum, liver, and esophagus. Population expansion, age, environmental pollution, and bad eating habits are all contributing to an increase in cancer burden and, as a result, cancer treatments.
Targeted therapy is a type of cancer treatment that differs from standard chemotherapy. The medicines used in target treatment operate by focusing on certain genes or proteins found in cancer cells. With the discovery of tumor cell-specific genes, recent advances in biological treatments have broadened the scope of therapeutic targets for cancer treatment. Among many cancer treatments, immunotherapies/biologics are developing as a promising therapy for finding a lasting cure for various cancer types.
Asia Pacific Cancer Therapies Market Trends, Drivers, Restraints, and Opportunities
-
Increasing support from the government in terms of initiatives and awareness programs regarding the hazardous effects of smoking is anticipated to spur market expansion in the coming years.
-
Expanding patient support programmes is estimated to drive market growth during the forecast period.
-
Treatment side effects and high therapy costs may impede market expansion over the predicted time.
Scope of Asia Pacific Cancer Therapies Market Report
The report on the Asia Pacific cancer therapies market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Asia Pacific Cancer Therapies Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016–2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Treatment Types (Chemotherapy, Target Therapy, Immunotherapy, Hormone Therapy, and Other Treatment Types), Cancer Types (Blood Cancer, Breast Cancer, Prostate Cancer, Gastrointestinal Cancer, Gynecologic Cancer, Respiratory/Lung Cancer, and Other Cancer Types), and End-users (Hospitals, Specialty Clinics, and Radiation Therapy Centre)
|
|
Countries Scope
|
China, Japan, India, Australia, South Korea, and Rest of Asia Pacific
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Amgen, Astra Zeneca, Bayer AG, Johnson & Johnson, and Merck & Co. Inc.
|
Asia Pacific Cancer Therapies Market Segment Insights
Target therapy segment is projected to account for a key market share
In terms of treatment types, the Asia Pacific cancer therapies market is bifurcated into chemotherapy, target therapy, immunotherapy, hormone therapy, and other treatment types. The target therapy segment is expected to account for a key share of the market during the forecast period owing to its selectivity for cancer cells while avoiding harm to non-target cells. A rise in R&D and the growing occurrence of various forms of cancer throughout the world are two additional significant reasons driving the segment's growth.
Respiratory/Lung cancer segment is expected to register at a rapid pace
On the basis of cancer types, the Asia Pacific cancer therapies market is segregated into blood cancer, breast cancer, prostate cancer, gastrointestinal cancer, gynecologic cancer, respiratory/lung cancer, and other cancer types. The respiratory/lung cancer segment is expected to account for a key share of the market in the coming years due to a surge in the cases of lung cancer in recent times.
Specialty clinics segment is anticipated to register at a rapid CAGR
In terms of end-users, the Asia Pacific cancer therapies market is divided into hospitals, specialty clinics, and radiation therapy centre. The hospitals segment is expected to account for a key share of the market during the forecast period owing to the rising prevalence of cancer cases and availability of hospitals in every place.
China is anticipated to dominate the market
On the basis of countries, the Asia Pacific cancer therapies market is classified as China, Japan, India, Australia, South Korea, and Rest of Asia Pacific. The market of China is anticipated to expand at an impressive CAGR during the forecast period. The countries’ market growth can be attributed to changing lifestyles.
Segments
The Asia Pacific cancer therapies market has been segmented on the basis of
Treatment Types
- Chemotherapy
- Target Therapy
- Immunotherapy
- Hormone Therapy
- Other Treatment Types
Cancer Types
- Blood Cancer
- Breast Cancer
- Prostate Cancer
- Gastrointestinal Cancer
- Gynecologic Cancer
- Respiratory/Lung Cancer
- Other Cancer Types
End-users
- Hospitals
- Specialty Clinics
- Radiation Therapy Centre
Countries
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
Key Players
- Amgen
- Astra Zeneca
- Bayer AG
- Johnson & Johnson
- Merck & Co. Inc.
Competitive Landscape
Key players competing in the Asia Pacific cancer therapies market include Amgen, Astra Zeneca, Bayer AG, Johnson & Johnson, and Merck & Co. Inc. Some of these players are investing in several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares.
Request For Customization
Enquiry Before Buying
Speak With Analyst
